Adjuvant treatment of HCC research hub

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

This study is looking at a new treatment called Keytruda for people who have had liver cancer removed by surgery or other procedures. It compares Keytruda to a dummy treatment (placebo) to see if it can stop the cancer from coming back and help people live longer.